Search
Displaying 491–500 of 624 for “retinal diseases”
-
Beacon Stories
“I try not to get my hopes up too much, but I never lose hope; I’m determined. I just want to see my son’s face, see him get married, & see my grandchildren. I encourage everyone with a retinal disease to get a genetic test & to never ever give up hope.“
-
Fighting Blindness Gets Sheepish
Research NewsResearchers in Israel are developing a gene therapy for achromatopsia that may help both sheep and humans alike.
-
ARVO 2016: ProgSTAR, FFB-CRI's Stargardt Disease Patient Study, Highlighted
Research NewsWhen the study and the reports are completed, the ProgSTAR database will be made available to researchers and companies developing therapies.
-
Gene Therapy Strengthens the Retina's Connection to the Brain
Research NewsWhat happens to the brain when the eye is enabled to see through gene therapy? Would the brain and eye restart their partnership? We now know the answer is yes.
-
ARVO 2014: European Collaboration Developing Cross-Cutting, Vision-Saving Therapies
Research NewsSimply put, they’re creating therapies that can save vision in as many people as possible, independent of the genetic cause of disease.
-
Turning Stem Cells Into "Super" Models
Research NewsScientists have found a way to take a small skin or blood sample from a patient, turn back the clock on those sample cells so they become stem cells, and then coax them forward to become photoreceptors, or any other cell type in the body.
-
The Foundation's 5 Most Asked Questions About Clinical Trials
Research NewsWhat you need to know (and what to expect) about clinical trials.
-
Research News
The study is designed to evaluate the pharmacodynamics, safety and tolerability of emixustat in subjects with macular atrophy secondary to Stargardt disease.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
.png)
